作者:Venkateshappa Chandregowda、Gudapati Venkateswara Rao、Goukanapalli Chandrasekara Reddy
DOI:10.1080/00397910701483761
日期:2007.9.1
Abstract A highly efficient and commercially viable process for the synthesis of 6,7‐dihydroxy‐4‐anilinoquinazoline derivatives gefitinib (1) and erlotinib hydrochloride (2), used for the treatment of non‐small cell lung cancer (NSCLC) and pancreatic cancer, is reported. This new process has improved yields and avoids the unstable 4‐chloroquinazoline intermediate. The intermediates and final products
摘要 一种合成 6,7-二羟基-4-苯胺基喹唑啉衍生物吉非替尼 (1) 和盐酸厄洛替尼 (2) 的高效且商业可行的方法,用于治疗非小细胞肺癌 (NSCLC) 和胰腺癌, 报道。这种新工艺提高了产量并避免了不稳定的 4-氯喹唑啉中间体。中间体和终产物通过 1H 和 13C 核磁共振 (NMR)、质谱 (MS) 和元素分析进行表征,最终产物的纯度通过高效液相色谱 (HPLC) 和电位滴定法测定。